MOESM1 of Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Liu, Tianshu; Qin, Yanru; Li, Jin; Xu, Ruihua; Xu, Jianming; Yang, Shujun; Qin, Shukui; Bai, Yuxian; Wu, Changping; Mao, Yixiang; Wu, Haiyan; Ge, Yilin; Shen, Lin

doi:10.6084/m9.figshare.8319167.v1

40880_2019_384_MOESM1_ESM.docx (12.4 kB)

MOESM1 of Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

journal contribution

posted on 2019-06-24, 05:00 authored by Tianshu Liu, Yanru Qin, Jin Li, Ruihua Xu, Jianming Xu, Shujun Yang, Shukui Qin, Yuxian Bai, Changping Wu, Yixiang Mao, Haiyan Wu, Yilin Ge, Lin Shen

Additional file 1: Table S1. Post-study anti-cancer therapies used by at least 2 patients (ITT population).

Funding

F. Hoffmann-La Roche

History

Usage metrics

Keywords

Gastric cancer Gastroesophageal junction cancer HER2 Pertuzumab Trastuzumab Chemotherapy Overall survival Progression-free survival Safety China

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM1 of Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Funding

F. Hoffmann-La Roche

History

Usage metrics

Categories

Keywords

Licence

Exports